Summary
Background: Statins are life saving drugs in cardiovascular practice. However, they still are underprescribed in many situations despite their well-established benefits. Adherence may be improved by increased comprehension of the patients.
Methods: Patients enrolled into a previous survey were randomized into two groups as those, who were informed comprehensively (Group 1) and those not (Group 2). 202 patients, all of whom were on secondary prevention, were contacted after median 15 months of follow up and evaluated whether they continued the statins, and reached targets.
Results: 102 out of 202 patients were those enrolled into Group 1, and 100 of them were those enrolled into Group 2. In Group 1, 62.7% of patients were on continuous statin therapy during period betweeen initial and secondary contact, whereas, only 46% of patients in Group 2 were on continuous statin therapy (p = 0.017). Being well-informed about statin increased the likelihood of being on continuous statin therapy after median of 15 months by 1.977 folds. Concerning targets, 64.7% of those in Group 1 reached the targets, whereas, 43% of those in Group 2 reached the targets (p = 0.002). Being well-informed about statin increased the likelihood of having suggested targets by ATP III after median of 15 months by 2.430 folds.
Conclusion: Providing patients with comprehensive knowledge about statins, even in patients, who were already on statin therapy, seems not only to improve adherence but also increase the percentage of those reaching targets.
Similar content being viewed by others
References
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal. Drug Saf 1996;14:11–24.
Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317–325.
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208–211.
Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance: A systematic review of the effect of continuing medication education strategies. JAMA 1995;274:700–705.
Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated reminder charts on patients’ compliance with drug regimens. BMJ 1993;306:1158–1161.
Tolmie EP, Lindsay GM, Kerr SM, Brown MR, Ford I, Gaw A. Patients’ perspectives on statin therapy for treatment of hypercholesterolaemia: a qualitative study. Eur J Cardiovasc Nurs 2003;2(2):141–149.
Kim YS, Sunwoo S, Lee HR, et al. Korea Post-Marketing Surveillance Research Group. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002;11(7):593–600.
Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart 2002;88(3):229–233.
Cannon CP, McCabe CH, Bentley J, Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI-16 [abstract]. J Am Coll Cardiol 2001;35:334A.
Muhlestein JB, Horne BD, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257–261.
Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of awareness of on-treatment patients about prescribed statins. Cardiovasc Drugs Ther 2004;18(5):399–404.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1283–1289.
The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.
Downs JR, Clearfield M, Whitney E, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615–1622.
Feussner G. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1994;5:59–68
Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;22(Suppl 3):13–23.
Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study. Can J Cardiol 2005;21(6):485–488.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yilmaz, M.B., Pinar, M., Naharci, I. et al. Being Well-Informed About Statin is Associated with Continuous Adherence and Reaching Targets. Cardiovasc Drugs Ther 19, 437–440 (2005). https://doi.org/10.1007/s10557-005-5202-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-005-5202-5